Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04)
Auteurs : Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I; GFPC Team.
